organ
start
locat
ivi
establish
intern
organ
vienna
convent
establish
initi
unit
nation
develop
program
undp
group
global
health
develop
commun
felt
need
independ
autonom
organ
mandat
develop
deliv
vaccin
lowincom
countri
countri
world
health
organ
sign
establish
agreement
ivi
format
select
committe
decid
institut
base
asia
competit
bid
made
six
asian
countri
appli
includ
south
korea
south
korea
ultim
chosen
ivi
host
countri
sever
reason
thrive
economi
burgeon
infrastructur
r
life
scienc
research
commit
made
korean
govern
support
ivi
first
intern
organ
headquart
south
korea
locat
campu
seoul
nation
univers
capit
citi
seoul
critic
problem
vaccineimmunotherapeut
develop
field
interest
vaccin
contribut
enorm
valu
societi
us
center
diseas
control
prevent
estim
unit
state
alon
vaccin
produc
direct
save
societi
nearli
billion
usd
critic
problem
unfortun
benefit
vaccin
vaccin
equal
distribut
global
accord
world
health
organ
estim
nearli
million
children
develop
countri
die
everi
year
vaccineprevent
diseas
second
problem
lie
develop
new
vaccin
big
three
ie
hiv
malaria
tb
also
diseas
exert
tremend
burden
group
streptococc
infect
dengu
vaccin
develop
lengthi
costli
endeavor
obtain
resourc
develop
vaccin
public
sector
especi
challeng
relat
third
issu
get
messag
funder
govern
popul
risk
develop
safe
effect
afford
vaccin
global
prioriti
access
effect
vaccin
right
respons
mission
organ
ivi
mission
discov
develop
deliv
safe
effect
afford
vaccin
global
public
health
vision
see
develop
countri
free
suffer
infecti
diseas
organ
facilit
vaccineimmunotherapeut
develop
ivi
mission
entail
discoveri
develop
deliveri
vaccin
discoveri
conduct
preclin
research
develop
new
vaccin
improv
process
vaccin
manufactur
implement
field
studi
identifi
global
burden
particular
diseas
target
ivi
vaccin
interest
develop
techtransf
vaccin
requir
manufactur
andor
scaleup
develop
countri
manufactur
provid
assist
applic
compani
design
regulatori
approv
pathway
execut
correspond
clinic
trial
also
provid
assist
compani
file
local
approv
andor
world
health
organ
prequalif
allow
sale
vaccin
un
agenc
final
deliveri
work
field
conduct
target
vaccin
demonstr
project
ivi
diseas
interest
well
diseas
surveil
epidemiolog
studi
gener
necessari
data
permit
inform
polici
decis
govern
organ
engag
nation
intern
resourc
commit
vaccineimmunotherapi
research
intern
organ
host
south
korea
ivi
receiv
support
korean
govern
swedish
govern
sweden
signatori
countri
ivi
treati
also
receiv
support
charit
foundat
bill
melinda
gate
foundat
pharmaceut
compani
eg
sanofi
pasteur
takeda
pfizer
msd
korean
compani
eg
lg
electron
kia
motor
light
recent
mer
outbreak
south
korea
recent
start
engag
samsung
medic
center
develop
merscov
vaccin
samsung
commit
million
usd
support
project
ivi
multilater
institut
recogn
organ
econom
cooper
develop
oecd
therefor
contribut
ivi
consid
offici
develop
assist
oda
also
recogn
c
nonprofit
organ
unit
state
import
partnership
organ
partnership
major
compon
ivi
work
achiev
mission
alon
intern
organ
statu
neutral
nonstat
actor
allow
us
engag
wide
varieti
group
govern
industri
academia
public
sector
publicpriv
partnership
civil
societi
put
vaccin
vaccin
agenda
gavi
vaccin
allianc
import
partner
particular
ivi
signatori
repres
board
besid
funder
import
group
partner
asian
vaccin
manufactur
scope
vari
depend
partner
provid
support
technic
assist
technolog
transfer
manufactur
scaleup
clinic
develop
evalu
regulatori
affair
current
partner
six
asianbas
compani
eubiolog
south
korea
sk
chemic
south
korea
vabiotech
vietnam
pt
biofarma
indonesia
incepta
vaccin
bangladesh
shantha
biotechn
india
partner
group
critic
work
term
make
vaccin
avail
access
middl
lowincom
countri
lmic
addit
support
provid
promot
capacitybuild
vaccin
sustain
lmic
posit
organ
director
gener
ivi
mean
lead
overse
institut
accord
ivi
origin
charter
director
gener
diplomat
statu
help
ivi
outreach
engag
other
vaccin
diplomaci
highlight
would
select
recent
vaccineimmunotherapi
research
develop
use
develop
inactiv
oral
cholera
vaccin
ocv
transfer
manufactur
vietnames
indian
bangladeshi
south
korean
manufactur
highlight
shanchol
manufactur
shantha
biotechn
whoprequalifi
vaccin
use
global
cholera
vaccin
stockpil
manag
deploy
combat
cholera
outbreak
countri
like
haiti
guinea
south
sudan
malawi
pleas
euvichol
produc
eubiolog
south
korea
manufactur
recent
whoprequalifi
help
increas
global
suppli
oral
cholera
vaccin
meet
demand
addit
euvichol
first
koreanmad
vaccin
global
health
proud
partner
south
korea
humanitarian
initi
ivi
lead
product
develop
partnership
support
korean
swedish
govern
gate
foundat
date
one
two
nonprofit
organ
fund
gate
foundat
success
develop
whoprequalifi
two
vaccin
ivi
lead
anoth
product
develop
partnership
new
lowcost
typhoid
fever
vaccin
use
infant
young
children
develop
countri
partner
sk
chemic
south
korea
pt
biofarma
indonesia
incepta
vaccin
bangladesh
clinic
test
sk
chemic
pt
biofarma
begin
soon
recent
respons
mer
outbreak
south
korea
samsung
commit
fund
ivi
help
develop
new
merscov
vaccin
look
forward
partner
samsung
group
acceler
develop
mer
vaccin
respons
global
health
problem
area
topic
organ
current
focu
histor
ivi
associ
enter
diarrheal
diseas
cholera
typhoid
dengu
major
program
focu
acceler
develop
introduct
safe
effect
afford
vaccin
diseas
continu
build
experi
expertis
diseas
area
also
smaller
program
noroviru
shigella
rotaviru
process
expand
includ
diseas
global
health
import
pneumococc
diseas
mer
rotaviru
hepat
e
tb
main
goal
next
year
join
ivi
month
ago
howev
identifi
four
main
goal
institut
first
build
firstinclass
vaccin
develop
capabl
asia
strengthen
core
compet
cholera
typhoid
dengu
extend
diseas
interest
global
public
health
pneumococc
diseas
mer
rotaviru
hepat
e
tb
second
strengthen
diversifi
relationship
key
stakehold
bill
melinda
gate
foundat
korean
swedish
govern
other
korean
vaccinebiotech
compani
develop
countri
manufactur
third
enhanc
capabl
effect
effici
develop
deliv
vaccin
time
budget
final
fourth
manag
ivi
growth
keep
eye
financi
sustain
inform
http
wwwiviorg
